📊 XNCR Key Takeaways
Is Xencor Inc (XNCR) a Good Investment?
Xencor is a pre-profitability biotech company with positive revenue growth (+13.7% YoY) but severe cash burn (-$138.3M FCF annually) that poses existential runway risk given only ~$54.1M in cash reserves. While the low debt/equity ratio (0.12x) and strong liquidity ratios provide near-term flexibility, the company cannot sustain current burn rates without additional financing, and lacks demonstrated path to profitability with -73.2% net margins.
Why Buy Xencor Inc Stock? XNCR Key Strengths
- Revenue growth of 13.7% YoY indicates market traction
- Low leverage (0.12x debt/equity) preserves financial flexibility
- Strong liquidity ratios (6.25x current ratio) enable near-term operations
- Improving EPS trend (+65.4% YoY reduction in losses)
XNCR Stock Risks: Xencor Inc Investment Risks
- Annual free cash flow of -$138.3M creates approximately 5-month cash runway
- Operating losses of -$177.5M indicate pre-revenue or inefficient operations
- Negative net margin of -73.2% with no clear path to profitability
- Dependency on successful clinical trials and regulatory approvals (undisclosed pipeline risk)
- Unsustainable cash burn rate requires capital raise or operational restructuring
Key Metrics to Watch
- Operating cash flow trend and quarterly burn rate trajectory
- Cash balance and working capital management
- Revenue per dollar of operating expense (burn efficiency)
- Clinical trial progression and regulatory milestone announcements
- Capital raise activities and financing runway extension
Xencor Inc (XNCR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.25x current ratio provides a solid financial cushion.
XNCR Profit Margin, ROE & Profitability Analysis
XNCR vs Healthcare Sector: How Xencor Inc Compares
How Xencor Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Xencor Inc Stock Overvalued? XNCR Valuation Analysis 2026
Based on fundamental analysis, Xencor Inc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Xencor Inc Balance Sheet: XNCR Debt, Cash & Liquidity
XNCR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Xencor Inc's revenue has declined by 37% over the 5-year period, indicating business contraction. The most recent EPS of $-2.20 indicates the company is currently unprofitable.
XNCR Revenue Growth, EPS Growth & YoY Performance
XNCR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $17.8M | -$6.0M | $-0.08 |
| Q2 2025 | $23.9M | -$30.8M | $-0.41 |
| Q1 2025 | $16.0M | -$48.4M | $-0.66 |
| Q3 2024 | $10.7M | -$24.3M | $-0.40 |
| Q2 2024 | $17.0M | -$22.0M | $-0.37 |
| Q1 2024 | $12.8M | -$60.8M | $-1.02 |
| Q3 2023 | $27.3M | -$24.3M | $-0.40 |
| Q2 2023 | $30.2M | -$10.4M | $-0.17 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Xencor Inc Dividends, Buybacks & Capital Allocation
XNCR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Xencor Inc (CIK: 0001326732)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 13, 2026 | 4 | xslF345X06/wk-form4_1776110503.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/wk-form4_1773086825.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/wk-form4_1773086802.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/wk-form4_1773086785.xml | View → |
| Mar 9, 2026 | 4 | xslF345X05/wk-form4_1773086762.xml | View → |
❓ Frequently Asked Questions about XNCR
What is the AI rating for XNCR?
Xencor Inc (XNCR) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XNCR's key strengths?
Claude: Revenue growth of 13.7% YoY indicates market traction. Low leverage (0.12x debt/equity) preserves financial flexibility.
What are the risks of investing in XNCR?
Claude: Annual free cash flow of -$138.3M creates approximately 5-month cash runway. Operating losses of -$177.5M indicate pre-revenue or inefficient operations.
What is XNCR's revenue and growth?
Xencor Inc reported revenue of $125.6M.
Does XNCR pay dividends?
Xencor Inc does not currently pay dividends.
Where can I find XNCR SEC filings?
Official SEC filings for Xencor Inc (CIK: 0001326732) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XNCR's EPS?
Xencor Inc has a diluted EPS of $-1.24.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XNCR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Xencor Inc has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XNCR stock overvalued or undervalued?
Valuation metrics for XNCR: ROE of -14.5% (sector avg: 15%), net margin of -73.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XNCR stock in 2026?
Our dual AI analysis gives Xencor Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XNCR's free cash flow?
Xencor Inc's operating cash flow is $-135.1M, with capital expenditures of $3.2M. FCF margin is -110.1%.
How does XNCR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -73.2% (avg: 12%), ROE -14.5% (avg: 15%), current ratio 6.25 (avg: 2).